Literature DB >> 12725951

Mechanism of action of IVIG and anti-D in ITP.

Alan H Lazarus1, Andrew R Crow.   

Abstract

Infusion of large amounts of intravenous immunoglobulin (IVIG) or polyclonal anti-D can reverse thrombocytopenia in patients with idiopathic thrombocytopenic purpura within hours of the administration of these products. It has been suggested that the effects of IVIG appear to far outlast several half-lives of the product. Several mechanisms have been proposed to explain both the acute and long term effects of IVIG. These will be discussed in this review.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12725951     DOI： 10.1016/S1473-0502(03)00043-0

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


  11 in total

1.  The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Authors:  Robert S Franco; Zahida Yasin; Mary B Palascak; Peter Ciraolo; Clinton H Joiner; Donald L Rucknagel
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

2.  Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.

Authors:  Sarah J Barsam; Bethan Psaila; Marc Forestier; Lemke K Page; Peter A Sloane; Julia T Geyer; Glynis O Villarica; Mary M Ruisi; Terry B Gernsheimer; Juerg H Beer; James B Bussel
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

Review 3.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

4.  [Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Authors:  Ingrid Pabinger; Günther Gastl; Michael Steurer; Siegfried Sormann; Michael Fillitz; Josef Friedl; Dietmar Geissler; Klaus Geissler; Richard Greil; Paul Knöbl; Sibylle Kozek-Langenecker; Peter Krippl; Paul Kyrle; Alois Lang; Werner Linkesch; Heinz Ludwig; Markus Müller; Simon Panzer; Elisabeth Pittermann; Josef Thaler; Ansgar Weltermann
Journal:  Wien Klin Wochenschr       Date:  2012-03-03       Impact factor: 1.704

5.  Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

Authors:  Ayesha M Khan; Halina Mydra; Ana Nevarez
Journal:  P T       Date:  2017-12

6.  Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

Authors:  Vinayakumar Siragam; Davor Brinc; Andrew R Crow; Seng Song; John Freedman; Alan H Lazarus
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

7.  Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.

Authors:  Rong Deng; Joseph P Balthasar
Journal:  Blood       Date:  2006-11-28       Impact factor: 22.113

8.  Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.

Authors:  Muhittin Celik; Ali Bulbul; Gönül Aydogan; Deniz Tugcu; Emrah Can; Sinan Uslu; Mesut Dursun
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 9.  A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report.

Authors:  Tarinee Rungjirajittranon; Weerapat Owattanapanich
Journal:  J Med Case Rep       Date:  2019-01-28

10.  Anti-RhD antibody therapy modulates human natural killer cell function.

Authors:  Shlomo Elias; Inbal Kol; Shira Kahlon; Rajaa Amore; Mariam Zeibak; Dror Mevorach; Uriel Elchalal; Orly Zelig; Ofer Mandelboim
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.